OREANDA-NEWS People with this disease lack a gene that converts light into signals for the brain and allows the eyes to see. Scientists hope that adding this gene with CRISPR will cure them.

As noted by AP, thanks to the Luxturna gene therapy already existing on the market, scientists know that the introduction of a replacement gene into retinal cells can cure this disease. CRISPR will work in the same way, bringing new genetic material to the eyes, giving researchers the opportunity to perform a simpler operation in the human body, before turning to more complex diseases such as cancer.

Two companies, Editas Medicine and Allergan, will test this technology in 18 hospitals throughout the United States starting in the fall of 2019. The study will affect dozens of children under the age of three and adults up to 50 years.